<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250529065959N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-06-25</date_registration>
      <primary_sponsor>University of Kurdistan</primary_sponsor>
      <public_title>The Effectiveness of the Unified Transdiagnostic Treatment on Internet Addiction comorbid with Emotional Disorders</public_title>
      <acronym></acronym>
      <scientific_title>The Effectiveness of Integrated Transdiagnostic Treatment on Improving Symptoms and Emotional Indicators in Individuals with Internet Addiction Comorbid with Other Emotional Disorders: A Randomized Controlled Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-07-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>34</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/84059</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Following the selection of individuals with Internet addiction comorbid with emotional disorders based on inclusion and exclusion criteria, they will be assigned to treatment and control groups using a minimization method. The purpose of this method is to control for the variable of gender. Thus, if the first participant is female, she will be placed in group number one. If the second participant is male, he will also be placed in the first group. If the third participant is female, she will be placed in the second group, and the remaining participants will be assigned to groups in the same manner, adjusting for the gender variable, Blinding description: In this study, a clinical interview will be conducted by an expert clinical therapist to assess inclusion and exclusion criteria. Participants will be randomly assigned to either the treatment or control group after providing informed consent to participate in the research, such that participants will be unaware of their group assignment (treatment or control). Group allocation of participants and administration of study tests at all three stages (pre-treatment, post-treatment, and 3-month follow-up) will be performed by someone other than the therapist.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Internet Addiction.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Integrative transdiagnostic therapy for emotional disorders involves up to 12 45-minute sessions. It targets and moderates emotional experiences by developing emotional awareness and cognitive flexibility; identifying emotional behaviors and replacing them with adaptive behaviors; identifying and preventing emotional avoidance; increasing awareness and exposure to physical sensations; and confronting emotions in the situation. Intervention 2: waitlist group: Group on the waiting list to receive integrated transdiagnostic treatment. After the follow-up sessions of the intervention groups are completed, integrated transdiagnostic treatment will be applied as in intervention group number one.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Some of the data, including information related to the main outcome, can be shared.

When:
Access begins one year after results are published.

To whom:
The data will only be available to researchers working at academic institutions.

Conditions:
Requests to use data are only permitted for use in cross-cultural surveys or meta-analytic studies.

Where to obtain:
Researchers can apply through the aforementioned communication channel to receive the desired documents or data. Email: nasiri.uok@yahoo.com

How to obtain:
The data information will be provided to individuals via email or post after the application is evaluated.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sara Karimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pasdaran Blvd.</address>
        <city>sanandaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>66177-15175</zip>
        <telephone>087-33664600-8</telephone>
        <email>sara.karimi@uok.ac.ir</email>
        <affiliation>University of Kurdistan</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Farzad Nasiri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pasdaran Blvd.</address>
        <city>Sanandaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>66177-15175</zip>
        <telephone>087-33664601-2246</telephone>
        <email>nasiri.uok@yahoo.com</email>
        <affiliation>The University of Kurdistan</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The diagnosis of internet addiction is based on a structured clinical interview and the use of Young's Internet Addiction Questionnaire with a minimum score of 46
Having at least one emotional disorder
An age range of 18-30 years
A willingness to cooperate and continue therapy sessions</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>30 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Using psychiatric medications or psychoactive substances,  , and
Having more than two absences
Receiving psychological interventions concurrently
Diagnosis of any psychological disorder other than those under investigation in the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F63.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other impulse disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Integrative transdiagnostic therapy for emotional disorders involves up to 12 45-minute sessions. It targets and moderates emotional experiences by developing emotional awareness and cognitive flexibility; identifying emotional behaviors and replacing them with adaptive behaviors; identifying and preventing emotional avoidance; increasing awareness and exposure to physical sensations; and confronting emotions in the situation.</i_keyword>
      <i_keyword>waitlist group: Group on the waiting list to receive integrated transdiagnostic treatment. After the follow-up sessions of the intervention groups are completed, integrated transdiagnostic treatment will be applied as in intervention group number one.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Internet Addiction score in Young Questionnare. Timepoint: before the treatment, after the treatment, 1 months after the end of the treatment. Method of measurement: Young Internet Addiction Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Depression score on the Beck Depression Inventory, second edition. Timepoint: Before treatment, after treatment, 1 months after the end of treatment. Method of measurement: Beck Depression Inventory, second edition.</sec_outcome>
      <sec_outcome>Anxiety score on the Beck Anxiety Questionnaire. Timepoint: Before treatment, after treatment, 1 months after completion of treatment. Method of measurement: Beck Anxiety Questionnaire.</sec_outcome>
      <sec_outcome>Difficulties in emotion regulation score. Timepoint: Before treatment, after treatment, 1 months after completion of treatment. Method of measurement: Difficulties in Emotion Regulation Scale.</sec_outcome>
      <sec_outcome>Experiential Avoidance score. Timepoint: Before treatment, after treatment, 1 months after completion of treatment. Method of measurement: Acceptance and Action Questionnaire-II.</sec_outcome>
      <sec_outcome>Distress Intolerance score. Timepoint: Before treatment, after treatment, 1 months after completion of treatment. Method of measurement: Distress Tolerance Scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>University of Kurdistan</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-05-18</approval_date>
        <contact_name>Ethics committee in Biomedical Research</contact_name>
        <contact_address>Pasdaran Blvd, University of Kurdistan, Central Organization Sanandaj Kurdistan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
